Factors associated with the choice of the first biologic in psoriasis: real‐life analysis from the Psobioteq cohort. (16th July 2017)

• Record Type: Journal Article
• Authors: Sbidian, E.; Giboin, C.; Bachelez, H.; Paul, C.; Beylot‐Barry, M.; Dupuy, A.; Viguier, M.; Lacour, J.‐P.; Schmutz, J.‐L.; Bravard, P.; Mahé, E.; Beneton, N.; Misery, L.; Delaporte, E.; Modiano, P.; Barbarot, S.; Regnier, E.; Jullien, D.; Richard, M.‐A.; Joly, P.; Tubach, F.; Chosidow, O.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 31:Number 12(2017)
• Page Start: 2046
• Page End: 2054
• Publication Date: 2017-07-16
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.14406
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: Decision‐making is a complex process. The aim of our study was to assess factors associated with the choice of the first biological treatment in patients with moderate‐to‐severe psoriasis. Methods: Data on all patients included in the French prospective, observational, cohort, Psobioteq and initiating a first biologic prescription between July 2012 and July 2016 were analysed. Demographic information and clinical features were collected during routine clinical assessments by the dermatology team at the recruiting centres using a standardized case report form. The primary outcome was the nature of the first biologic treatment. Four groups were identified as follows: adalimumab, etanercept, ustekinumab and infliximab groups. Factors associated with the choice of the first biological agent were determined by a multinomial logistic regression model adjusted on year of inclusion. Results: The study population included the 830 biological‐naïve patients who initiated a first biological agent. The mean age was 46.6 years (±SD 13.9), and 318 patients (38.3%) were female. The most commonly prescribed biologic was adalimumab: 355 (42.8%) patients, then etanercept ( n = 247, 29.8%), ustekinumab ( n = 194, 23.4%) and infliximab ( n = 34, 4.0%). In the multinomial logistic regression analysis, patients were significantly more likely to receive adalimumab if they had a severe psoriasis as defined by baseline PASI or if they had psoriatic arthritis compared to etanercept (aOR, 0.42; 95% CI, 0.16–1.07) and ustekinumab (aOR, 0.15; 95% CI, 0.04–0.52). Patients were significantly more likely to receive ustekinumab (aOR, 2.39; 95% CI, 1.04–5.50) if they had a positive screening for latent tuberculosis compared to adalimumab. Younger patients were also more likely to receive ustekinumab. Patients with chronic obstructive pulmonary disease were more likely to be prescribed ustekinumab or etanercept compared to adalimumab. There was a trend in favour of etanercept prescription in patients with cardiovascular comorbidities, metabolic syndrome and in patients with a history of cancer. Conclusion: We identified patient‐ and disease‐related factors that have important influence on the choice of the first biological agent in clinical practice. Clinicians appear to have a holistic approach to patient characteristics when choosing a biological agent in psoriasis.